Diversigen, Inc, Houston, Texas, USA.
Am J Gastroenterol. 2019 Jul;114(7):1030-1031. doi: 10.14309/ajg.0000000000000180.
Although causal relationships between specific microbes and cancer are well recognized, a growing body of evidence suggests that the broader community of gut microbes may influence cancer risk, provide diagnostic insight, shape clinical course, and impact treatment success in the gastrointestinal tract and beyond. In this issue, Murphy et al. reviewed evidence for the role of the microbiome in clinical oncology. Given that the gut microbiome may be modified by treatments ranging from diet and live biotherapeutics to microbial transplantation, microbiome-directed therapies hold tremendous promise for personalized therapies and improved treatment outcomes.
虽然特定微生物与癌症之间的因果关系已得到充分认识，但越来越多的证据表明，肠道微生物群落的广泛多样性可能会影响癌症风险，提供诊断见解，影响胃肠道和其他部位的临床病程，并影响治疗效果。在本期杂志中，Murphy 等人综述了微生物组在临床肿瘤学中的作用的证据。鉴于肠道微生物组可能会因饮食和活体生物治疗剂到微生物移植等治疗方法而发生改变，因此，针对微生物组的治疗方法为实现个体化治疗和改善治疗效果带来了巨大的希望。
